Reuters -- AstraZeneca’s cancer drug Recentin failed in a head to head late stage trial with Roche’s Avastin in colorectal cancer patients, hurting the Anglo-Swedish drugmaker’s shares on Monday. The company said the data, which analysts had expected to be negative for Recentin, showed the experimental drug did not meet its primary endpoint in the Horizon phase III study.
